US guidance highlights cardiovascular benefits of hypoglycemic drugs

Cardiologists urged to consider for patients with atherosclerosis and type 2 diabetes

A new report from the American College of Cardiology focuses on how to use novel medications to cut the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes and atherosclerotic cardiovascular disease.

This "much needed, useful guidance document" will "assist cardiovascular clinicians in understanding optimal management of our patients who suffer from diabetes and heart disease," Dr James Januzzi of Massachusetts General Hospital, in Boston, who chaired the expert consensus decision pathways